Twist Bioscience Corp (TWST) Chief Accounting Officer Robert F. Werner reported selling 1,482 shares of common stock on October 2, 2026, at $188.8840 per share. The shares were sold to cover tax withholding obligations tied to vesting of restricted stock units under the issuer’s equity incentive plans; the footnote describes these as mandated sell-to-cover transactions, not discretionary trades. Werner held 42,917 shares directly after the sale. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) is the issuer in a Rule 144 notice for officer Paula Green's proposed sale of 10,088 common shares, with aggregate market value $1,905,459.77. The approximate sale date is October 2, 2026; Fidelity Brokerage Services LLC is listed as broker and NASDAQ as the exchange. The shares are from restricted stock vesting dated October 1, 2026; the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. Jared Cook signed as the broker's duly authorized representative and Paula Green's attorney-in-fact.
Twist Bioscience Corp. officer Robert F. Werner reported a proposed sale of 1,482 common shares, with an aggregate market value of $279,925.79. The notice lists October 2, 2026 as the approximate sale date and Fidelity Brokerage Services LLC as the broker. The shares were listed as acquired through restricted stock vesting on October 1, 2026; the sale includes an amount necessary to cover the tax obligation resulting from settlement of a vested equity award distribution.
Twist Bioscience Corp officer Dennis H. Cho reported a proposed sale of 9,514 common shares, with an approximate aggregate market value of $1,797,040.47 and an approximate sale date of October 2, 2026. The shares are listed as acquired through restricted stock vesting on October 1, 2026. The notice states that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Twist Bioscience Corp. is identified as issuer in a Rule 144 notice naming officer and director Emily M. Leproust for a proposed sale of 45,736 common shares, with an aggregate market value of $8,638,789.48 and an approximate sale date of October 2, 2026. The shares were acquired from the issuer through restricted stock vesting on October 1, 2026; sale remarks state that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Twist Bioscience Corp (TWST) reported that officer Adam Laponis plans to sell 8,057 common shares, with an aggregate market value of $1,521,836.78 and an approximate sale date of October 2, 2026. The shares are associated with restricted stock vesting on October 1, 2026; the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Patrick Finn, an officer of Twist Bioscience Corp, gave notice of a proposed sale of 25,714 common shares at an aggregate market value of $4,856,958.03, with an approximate sale date of October 2, 2026. The shares came from restricted stock vesting on October 1, 2026; the sale includes an amount necessary for a tax obligation from settlement of a vested equity award distribution. Earlier reported sales were 2,238 shares on July 23, 2026; 2,888 on August 3, 2026; 78,355 on August 18, 2026; and 4,046 on August 21, 2026.
Twist Bioscience Corp (TWST) director and officer Emily M. Leproust is named in a Rule 144 notice for a proposed sale of 655 common shares through Fidelity Brokerage Services LLC. The proposed sale has an aggregate market value of $131,000.00 and an approximate sale date of October 1, 2026. The listed prior sales include 356,546 shares for $56,330,878.38 on September 17, 2026.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust sold 5,203 shares of common stock in ten transactions on September 24, 2026, under a Rule 10b5-1 trading plan adopted June 15, 2026. The reported weighted-average sale prices and share amounts were 2,485 at $175.2313; 945 at $176.3917; 164 at $177.1699; 330 at $178.6683; 143 at $179.9331; 515 at $180.3911; 21 at $181.4519; 16 at $182.5000; 501 at $183.7641; and 83 at $184.6030 per share.
Twist Bioscience Corp (TWST) has a Form 144 notice naming Emily M. Leproust as the account holder for a proposed sale of 5,203 common shares through Fidelity Brokerage Services LLC. The notice gives an aggregate market value of $922,906.47 and an approximate sale date of September 24, 2026. It also lists prior sales, including 356,546 common shares on September 17, 2026, with a reported value of $56,330,878.38.